Victory Capital Management Inc. Has $3.25 Million Stock Position in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Victory Capital Management Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 1,067.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 147,982 shares of the life sciences company’s stock after purchasing an additional 135,308 shares during the quarter. Victory Capital Management Inc. owned approximately 0.19% of Integra LifeSciences worth $3,254,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Quadrant Capital Group LLC boosted its holdings in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 1,371 shares during the period. Sterling Capital Management LLC raised its position in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after acquiring an additional 1,931 shares in the last quarter. Covestor Ltd raised its position in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock valued at $123,000 after acquiring an additional 2,071 shares in the last quarter. CWM LLC raised its position in Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock valued at $147,000 after acquiring an additional 5,367 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new position in Integra LifeSciences during the first quarter valued at approximately $223,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. JMP Securities cut their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Friday, May 9th. Finally, Wells Fargo & Company dropped their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.63.

Integra LifeSciences Trading Up 3.1%

Shares of IART stock opened at $13.11 on Monday. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $32.19. The firm’s fifty day simple moving average is $12.61 and its 200 day simple moving average is $17.93. The firm has a market capitalization of $1.02 billion, a P/E ratio of -34.50, a price-to-earnings-growth ratio of 0.73 and a beta of 1.15. The company has a current ratio of 1.21, a quick ratio of 0.72 and a debt-to-equity ratio of 0.81.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. During the same period last year, the firm posted $0.55 EPS. The company’s revenue was up 3.7% compared to the same quarter last year. As a group, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.